Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarloxotinib in Recurrent/Metastatic HNSCC or Skin SCC
NCT02449681Phase 2Terminated
- Sponsor
- Rain Oncology Inc.
- Start
- Aug 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tarloxotinib in head and neck squamous cell carcinoma (HNSCC), cutaneous squamous cell carcinoma (cSCC), sponsored by Rain Oncology Inc.. Started Aug 2015; status: terminated.
02
Drugs
tarloxotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT02449681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449681.